TY - JOUR T1 - Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy JF - Anticancer Research JO - Anticancer Res SP - 2043 LP - 2051 DO - 10.21873/anticanres.13315 VL - 39 IS - 4 AU - MARKOS ANTONOPOULOS AU - STEFAAN W. VAN GOOL AU - DIMITRA DIONYSIOU AU - NORBERT GRAF AU - GEORGIOS STAMATAKOS Y1 - 2019/04/01 UR - http://ar.iiarjournals.org/content/39/4/2043.abstract N2 - Background/Aim: The need for more effective treatment modalities that can improve the clinical outcome of patients with glioblastoma multiforme remains imperative. Dendritic cell vaccination is a fast-developing treatment modality, currently under exploration. Functional immune cell subpopulations may play a role in the final outcome. Materials and Methods: Data from 101 patients drawn from the HGG-2010 trial, including baseline patient characteristics and fluorescence-activated cell sorting of immune cell subpopulations, were analyzed by statistical and machine-learning methods. Results: The analysis revealed strong correlations between immune profiles and overall survival, when the extent of resection and the vaccination schedule were used as stratification variables. Conclusion: A systematic, in silico workflow detecting strong and statistically significant correlations between overall survival and immune profile-derived quantities obtained at the start of dendritic cell vaccination was devised. The derived correlations could serve as a basis for the identification of prognostic markers discriminating between potential long- and short-term survivors of patients with glioblastoma multiforme. ER -